Pub Date : 2023-11-12DOI: 10.3390/hematolrep15040063
Swati Garg, Wei Ni, James D. Griffin, Martin Sattler
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy that is often associated with relapse and drug resistance after standard chemotherapy or targeted therapy, particularly in older patients. Hematopoietic stem cell transplants are looked upon as the ultimate salvage option with curative intent. Adoptive cell therapy using chimeric antigen receptors (CAR) has shown promise in B cell malignancies and is now being investigated in AML. Initial clinical trials have been disappointing in AML, and we review current strategies to improve efficacy for CAR approaches. The extensive number of clinical trials targeting different antigens likely reflects the genetic heterogeneity of AML. The limited number of patients reported in multiple early clinical studies makes it difficult to draw conclusions about CAR safety, but it does suggest that the efficacy of this approach in AML lags behind the success observed in B cell malignancies. There is a clear need not only to improve CAR design but also to identify targets in AML that show limited expression in normal myeloid lineage cells.
{"title":"Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations","authors":"Swati Garg, Wei Ni, James D. Griffin, Martin Sattler","doi":"10.3390/hematolrep15040063","DOIUrl":"https://doi.org/10.3390/hematolrep15040063","url":null,"abstract":"Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy that is often associated with relapse and drug resistance after standard chemotherapy or targeted therapy, particularly in older patients. Hematopoietic stem cell transplants are looked upon as the ultimate salvage option with curative intent. Adoptive cell therapy using chimeric antigen receptors (CAR) has shown promise in B cell malignancies and is now being investigated in AML. Initial clinical trials have been disappointing in AML, and we review current strategies to improve efficacy for CAR approaches. The extensive number of clinical trials targeting different antigens likely reflects the genetic heterogeneity of AML. The limited number of patients reported in multiple early clinical studies makes it difficult to draw conclusions about CAR safety, but it does suggest that the efficacy of this approach in AML lags behind the success observed in B cell malignancies. There is a clear need not only to improve CAR design but also to identify targets in AML that show limited expression in normal myeloid lineage cells.","PeriodicalId":12954,"journal":{"name":"Hematology Reviews","volume":"23 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135037063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-01DOI: 10.3390/hematolrep15040062
Karla Rener, Saša Anžej Doma, Martina Fink, Helena Podgornik, Irena Preložnik Zupan
Prophylactic treatment with emicizumab has become an important and effective bleeding prevention for people with hemophilia A (PwHA). Perioperative management of PwHA using emicizumab prophylaxis is still challenging due to a lack of experience. Medical records of perioperative management and outcomes were reviewed, and data were collected for adult PwHA receiving emicizumab and undergoing surgical procedures between August 2019 and July 2022 at the University Medical Center Ljubljana. Twelve surgical procedures were performed in eight PwHA (one with FVIII inhibitors) while on emicizumab prophylaxis. Three minor procedures included cataract surgery, cystoscopic lithotripsy, and percutaneous coronary intervention. Nine major surgeries included four osteosyntheses, necrectomy of chronic osteomyelitis with new ankle arthrodesis, two below-knee amputations, total knee replacement, and placement of ventriculostomy after a spontaneous intraventricular hemorrhage. No major bleeds, thrombotic events or deaths, or new inhibitors appeared. Our real-world experience demonstrates that minor and major surgeries can be performed safely in PwHA on emicizumab prophylaxis. Additional data are needed to optimize dosing/duration of additional hemostatic agents in diverse invasive procedures and complex clinical situations.
{"title":"Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience","authors":"Karla Rener, Saša Anžej Doma, Martina Fink, Helena Podgornik, Irena Preložnik Zupan","doi":"10.3390/hematolrep15040062","DOIUrl":"https://doi.org/10.3390/hematolrep15040062","url":null,"abstract":"Prophylactic treatment with emicizumab has become an important and effective bleeding prevention for people with hemophilia A (PwHA). Perioperative management of PwHA using emicizumab prophylaxis is still challenging due to a lack of experience. Medical records of perioperative management and outcomes were reviewed, and data were collected for adult PwHA receiving emicizumab and undergoing surgical procedures between August 2019 and July 2022 at the University Medical Center Ljubljana. Twelve surgical procedures were performed in eight PwHA (one with FVIII inhibitors) while on emicizumab prophylaxis. Three minor procedures included cataract surgery, cystoscopic lithotripsy, and percutaneous coronary intervention. Nine major surgeries included four osteosyntheses, necrectomy of chronic osteomyelitis with new ankle arthrodesis, two below-knee amputations, total knee replacement, and placement of ventriculostomy after a spontaneous intraventricular hemorrhage. No major bleeds, thrombotic events or deaths, or new inhibitors appeared. Our real-world experience demonstrates that minor and major surgeries can be performed safely in PwHA on emicizumab prophylaxis. Additional data are needed to optimize dosing/duration of additional hemostatic agents in diverse invasive procedures and complex clinical situations.","PeriodicalId":12954,"journal":{"name":"Hematology Reviews","volume":"56 7-8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135271792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. El-Ashry, M. M. El-Ayuoty, H. Azzam, M. A. El-Naggar
Background: Childhood epilepsy is one of the most common neurological disorders in pediatrics . The prevalence of active epilepsy is 5–8 per 1000 population in developed countries and 10 per 1000 population in developing nations . There is a significant relationship between epilepsy and cognitive deficits. Aim of study: prospective study to evaluate the effect of the most commonly used anti-epileptics drugs on plasma fibrinogen level. Patient and methods 100 newly diagnosed patients (2months to 15 years old) selected from Outpatient Clinic of Neurology attending Mansoura University Children’s Hospital for plasma fibrinogen level evaluation by taking basal sample and second sample after six months after the basal one. Results: This study showed that, significant positive correlation between plasma fibrinogen level and the use of antiepileptic drugs. Conclusion: epileptic patient should be closely monitored during Antiepileptic drugs treatment and prior to surgical procedures as they can affect plasma fibrinogen level and coagulation profile. INTRODUCTION Epilepsy is a common illness worldwide. It is estimated that 0.5-1% of all children have epilepsy, with the majority presenting during infancy or early childhood (1). Epileptic seizures result from abnormal, excessive or hypersynchronous neuronal activity in the brain. About 50 million people worldwide have epilepsy, and nearly 80% of epilepsy occurs in developing countries(2 ). Antiepileptic drugs (AED) have been associated with adverse effects on the coagulation system. Carbamazepine, phenytoin and valproic acid can cause thrombocytopenia , Additionally, valproic acid and gabapentin have been associated with acquired von Willebrand disease type 1, hypofibrinogenemia ,decreased factorXIII and abnormal platelet function. (3). Coagulopathies were reported in children treated with VPA (>4%), but this is likely to be significantly underestimated. These children were reported with platelet dysfunction, thrombocytopenia, hypofibrinogenemia, acquired Von Wilbrand disease, Factor XIII deficiency and vitamin K-dependent factor deficiency (4). Little is known about the hematological side effects of the newer antiepileptic drugs (AEDs), but recent case reports have raised concerns regarding the possibility of altered coagulation profile, thrombocyte counts or function in some patients during levetiracetam (LEV) treatment. .( 5) Carbmazepines have been reported to be associated with clotting defects including: elevated prothrombin time, elevated partial thromboplastin time, though the exact mechanism is not known yet (6). PATIENT AND METHODS In this Observational Prospective Study, One hundred newly diagnosed patients will be included. They will be selected from the patients attended to Mansoura University Children Hospital at Outpatient Clinic of Neurology. This study was conducted on One hundred newly diagnosed patients with age ranging from 2 months to 15 years. In This study, we search for plasma fibrino
{"title":"Effect of antiepileptic drugs on plasma fibrinogen level","authors":"R. El-Ashry, M. M. El-Ayuoty, H. Azzam, M. A. El-Naggar","doi":"10.4081/hr.2020.7952","DOIUrl":"https://doi.org/10.4081/hr.2020.7952","url":null,"abstract":"Background: Childhood epilepsy is one of the most common neurological disorders in pediatrics . The prevalence of active epilepsy is 5–8 per 1000 population in developed countries and 10 per 1000 population in developing nations . There is a significant relationship between epilepsy and cognitive deficits. Aim of study: prospective study to evaluate the effect of the most commonly used anti-epileptics drugs on plasma fibrinogen level. Patient and methods 100 newly diagnosed patients (2months to 15 years old) selected from Outpatient Clinic of Neurology attending Mansoura University Children’s Hospital for plasma fibrinogen level evaluation by taking basal sample and second sample after six months after the basal one. Results: This study showed that, significant positive correlation between plasma fibrinogen level and the use of antiepileptic drugs. Conclusion: epileptic patient should be closely monitored during Antiepileptic drugs treatment and prior to surgical procedures as they can affect plasma fibrinogen level and coagulation profile. INTRODUCTION Epilepsy is a common illness worldwide. It is estimated that 0.5-1% of all children have epilepsy, with the majority presenting during infancy or early childhood (1). Epileptic seizures result from abnormal, excessive or hypersynchronous neuronal activity in the brain. About 50 million people worldwide have epilepsy, and nearly 80% of epilepsy occurs in developing countries(2 ). Antiepileptic drugs (AED) have been associated with adverse effects on the coagulation system. Carbamazepine, phenytoin and valproic acid can cause thrombocytopenia , Additionally, valproic acid and gabapentin have been associated with acquired von Willebrand disease type 1, hypofibrinogenemia ,decreased factorXIII and abnormal platelet function. (3). Coagulopathies were reported in children treated with VPA (>4%), but this is likely to be significantly underestimated. These children were reported with platelet dysfunction, thrombocytopenia, hypofibrinogenemia, acquired Von Wilbrand disease, Factor XIII deficiency and vitamin K-dependent factor deficiency (4). Little is known about the hematological side effects of the newer antiepileptic drugs (AEDs), but recent case reports have raised concerns regarding the possibility of altered coagulation profile, thrombocyte counts or function in some patients during levetiracetam (LEV) treatment. .( 5) Carbmazepines have been reported to be associated with clotting defects including: elevated prothrombin time, elevated partial thromboplastin time, though the exact mechanism is not known yet (6). PATIENT AND METHODS In this Observational Prospective Study, One hundred newly diagnosed patients will be included. They will be selected from the patients attended to Mansoura University Children Hospital at Outpatient Clinic of Neurology. This study was conducted on One hundred newly diagnosed patients with age ranging from 2 months to 15 years. In This study, we search for plasma fibrino","PeriodicalId":12954,"journal":{"name":"Hematology Reviews","volume":"254 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76334675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesco Romano, A. Giannone, S. Siragusa, R. Porcasi, A. Florena
Author’s contributions: Francesco Romano conceived, designed and performed the experiment, analyzed the data and wrote the manuscript. Antonino Giulio Giannone designed the experiment, analyzed the data and designed the figures. Sergio Siragusa wrote and revised the manuscript. Rossana Porcasi performed the experiment and analyzed the data. Ada Maria Florena provided the samples, wrote and revised the manuscript.
作者贡献:Francesco Romano构思，设计和执行实验，分析数据并撰写手稿。Antonino Giulio Giannone设计了实验，分析了数据并设计了图表。Sergio Siragusa撰写并修改了手稿。罗萨娜·波尔卡西进行了实验并分析了数据。Ada Maria Florena提供了样本，撰写并修改了手稿。
{"title":"Immunoistochemical expression of PD-1 and PD-L1 in bone marrow biopsies of patients with acute myeloid leukemia","authors":"Francesco Romano, A. Giannone, S. Siragusa, R. Porcasi, A. Florena","doi":"10.4081/hr.2020.8211","DOIUrl":"https://doi.org/10.4081/hr.2020.8211","url":null,"abstract":"Author’s contributions: Francesco Romano conceived, designed and performed the experiment, analyzed the data and wrote the manuscript. Antonino Giulio Giannone designed the experiment, analyzed the data and designed the figures. Sergio Siragusa wrote and revised the manuscript. Rossana Porcasi performed the experiment and analyzed the data. Ada Maria Florena provided the samples, wrote and revised the manuscript.","PeriodicalId":12954,"journal":{"name":"Hematology Reviews","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73918736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Noto, A. Bugatti, Michela Bertuzzi, Alessandra Dossi, F. Maffina, L. Paolini, A. Radeghieri, L. Caimi, M. Rusnati, D. Ricotta
{"title":"Biological role of immunoglobulin Free light chains interactomes","authors":"G. Noto, A. Bugatti, Michela Bertuzzi, Alessandra Dossi, F. Maffina, L. Paolini, A. Radeghieri, L. Caimi, M. Rusnati, D. Ricotta","doi":"10.4081/hr.2015.5946","DOIUrl":"https://doi.org/10.4081/hr.2015.5946","url":null,"abstract":"","PeriodicalId":12954,"journal":{"name":"Hematology Reviews","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76946489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Girolami, C. Esmon, M. Cattaneo, A. Spyropoulos, F. Piovella
10th International Winter Meeting on Coagulation,Basic, Laboratory and Clinical Aspects of Venous and Arterial Thromboembolic Diseases Bormio, April 10-16, 2011. With the auspices of ALT (Associazione per la Lotta alla Trombosi e alle malattie cardiovascolari – Onlus) FCSA (Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche) SISET (Societa Italiana per lo Studio della Emostasi e della Trombosi) Scientific Committee Armando D’Angelo (Milano, Italy), Antonio Girolami (Padova, Italy), Charles T. Esmon (Oklahoma City, OK, USA), Marco Cattaneo (Milano, Italy), Alexander Spyropoulos (Hamilton, ON, Canada) Franco Piovella (Pavia, Italy)
2011年4月10日至16日。协会With the auspices of ALT(心血管血栓形成和抗击疾病—中心联合会(欢迎)FCSA血栓的诊断和治疗监测Antitrombotiche) SISET(意大利社会研究Emostasi和血栓形成)科学委员会的武装分支(米兰、意大利)、安东尼奥·Girolami(帕多瓦、意大利),查尔斯·T . Esmon(俄克拉荷马城,好吧,美国)、卡塔(米兰、意大利)、亚历山大·马克Spyropoulos(汉密尔顿,,(加拿大)弗朗哥·皮奥维拉(意大利帕维亚)
{"title":"10th International Winter Meeting on Coagulation. Basic, Laboratory and Clinical Aspects of Venous and Arterial Thromboembolic Diseases. Bormio, Italy, April 10-16, 2011","authors":"A. Girolami, C. Esmon, M. Cattaneo, A. Spyropoulos, F. Piovella","doi":"10.4081/HR.2011.S1","DOIUrl":"https://doi.org/10.4081/HR.2011.S1","url":null,"abstract":"10th International Winter Meeting on Coagulation,Basic, Laboratory and Clinical Aspects of Venous and Arterial Thromboembolic Diseases Bormio, April 10-16, 2011. With the auspices of ALT (Associazione per la Lotta alla Trombosi e alle malattie cardiovascolari – Onlus) FCSA (Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche) SISET (Societa Italiana per lo Studio della Emostasi e della Trombosi) Scientific Committee Armando D’Angelo (Milano, Italy), Antonio Girolami (Padova, Italy), Charles T. Esmon (Oklahoma City, OK, USA), Marco Cattaneo (Milano, Italy), Alexander Spyropoulos (Hamilton, ON, Canada) Franco Piovella (Pavia, Italy)","PeriodicalId":12954,"journal":{"name":"Hematology Reviews","volume":"168 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2012-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76576875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Al-Hilali, Aisha M. Al-Jallaf, Sajida Chunkasseril
Thirty-four blood samples of neonates in Dubai, UAE, with an MCV below 90 fL were checked by high performance liquid chromatography (HPLC) for hemoglobin variants to confirm a previous study carried out in Western Province of Saudi Arabia which showed a very high predictive index of such MCV for alpha (α-) thalassemia minor (ATM). MCH below 30 pg was an additional factor which supported such a prediction. The Dubai study confirmed the original finding with 100% of such neonates showing Hb Barts band. A control group of 26 neonates with an MCV between 90 and 95 fl showed Hb Barts in only 11 cases (42.3%). Of these, 6 (23.1%) were preterm babies, expected to have higher MCV. Five cases (19.2%) had an MCH below 30 pg, though MCV was 90 or higher. Three of the preterm babies also had MCH below 30. The study confirmed the Saudi results in neonates. It seems very highly probable that a term neonate with MCV below 90 and MCH below 30 has ATM.
{"title":"Confirmation of the validity of using birth MCV for the diagnosis of alpha thalassemia trait","authors":"A. Al-Hilali, Aisha M. Al-Jallaf, Sajida Chunkasseril","doi":"10.4081/hr.2009.e20","DOIUrl":"https://doi.org/10.4081/hr.2009.e20","url":null,"abstract":"Thirty-four blood samples of neonates in Dubai, UAE, with an MCV below 90 fL were checked by high performance liquid chromatography (HPLC) for hemoglobin variants to confirm a previous study carried out in Western Province of Saudi Arabia which showed a very high predictive index of such MCV for alpha (α-) thalassemia minor (ATM). MCH below 30 pg was an additional factor which supported such a prediction. The Dubai study confirmed the original finding with 100% of such neonates showing Hb Barts band. A control group of 26 neonates with an MCV between 90 and 95 fl showed Hb Barts in only 11 cases (42.3%). Of these, 6 (23.1%) were preterm babies, expected to have higher MCV. Five cases (19.2%) had an MCH below 30 pg, though MCV was 90 or higher. Three of the preterm babies also had MCH below 30. The study confirmed the Saudi results in neonates. It seems very highly probable that a term neonate with MCV below 90 and MCH below 30 has ATM.","PeriodicalId":12954,"journal":{"name":"Hematology Reviews","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86726897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The β-globin gene mutation in sickle cell anemia results in anemia and repeated bouts of vascular occlusion. The cumulative effect of these vasocclusive events is progressive damage to many organs including the kidneys, lungs, and brain. The transfusion of red blood cells (RBC) can ameliorate many of these complications, but can be associated with both acute and chronic complications, including iron overload. The objective of the Best Practices in Transfusion Medicine for Patients with Sickle Cell Disease (SCD) Conference was to review the available published evidence and clinical experience surrounding the use of RBC transfusions for sickle cell disease by a panel of experts. The expert panel developed explicit clinical guidelines for the use of RBC in SCD patients. The panel also made recommendations for further research. A set of guidelines were produced for dissemination to pertinent stakeholders. If implemented, these clinical pathways have the potential to optimize the use of red blood cell transfusions in SCD.
{"title":"Best practices for transfusion for patients with sickle cell disease","authors":"T. Wun, K. Hassell","doi":"10.4081/hr.2009.e22","DOIUrl":"https://doi.org/10.4081/hr.2009.e22","url":null,"abstract":"The β-globin gene mutation in sickle cell anemia results in anemia and repeated bouts of vascular occlusion. The cumulative effect of these vasocclusive events is progressive damage to many organs including the kidneys, lungs, and brain. The transfusion of red blood cells (RBC) can ameliorate many of these complications, but can be associated with both acute and chronic complications, including iron overload. The objective of the Best Practices in Transfusion Medicine for Patients with Sickle Cell Disease (SCD) Conference was to review the available published evidence and clinical experience surrounding the use of RBC transfusions for sickle cell disease by a panel of experts. The expert panel developed explicit clinical guidelines for the use of RBC in SCD patients. The panel also made recommendations for further research. A set of guidelines were produced for dissemination to pertinent stakeholders. If implemented, these clinical pathways have the potential to optimize the use of red blood cell transfusions in SCD.","PeriodicalId":12954,"journal":{"name":"Hematology Reviews","volume":"115 15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84186232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mesenteric panniculitis (MP) is a rare disease occasionally complicated with lymphoma. A 55-year old female presented with MP accompanied by malignant lymphoma. This patient was first treated for follicular lymphoma and subsequently for panniculitis. After 6 courses of R-CHOP chemotherapy, the treatment response was partial. An additional course of salvage chemotherapy led to a complete response. Since the mesenteric mass progressed simultaneously with the regression of other lymphoma lesions, we performed a biopsy of the mesenteric mass and pathologically confirmed an MP lesion without lymphoma. Subsequent high-dose chemotherapy led to CR and the MP lesion remained stable. In the present case, MP progressed with chemotherapy. We concluded that mesenteric lesions suspected of progressing or recurring should be diagnosed pathologically even if asymptomatic.
{"title":"A case of follicular lymphoma complicated with mesenteric panniculitis","authors":"Y. Tamai, O. Imataki, I. Ito, K. Kawakami","doi":"10.4081/hr.2009.e17","DOIUrl":"https://doi.org/10.4081/hr.2009.e17","url":null,"abstract":"Mesenteric panniculitis (MP) is a rare disease occasionally complicated with lymphoma. A 55-year old female presented with MP accompanied by malignant lymphoma. This patient was first treated for follicular lymphoma and subsequently for panniculitis. After 6 courses of R-CHOP chemotherapy, the treatment response was partial. An additional course of salvage chemotherapy led to a complete response. Since the mesenteric mass progressed simultaneously with the regression of other lymphoma lesions, we performed a biopsy of the mesenteric mass and pathologically confirmed an MP lesion without lymphoma. Subsequent high-dose chemotherapy led to CR and the MP lesion remained stable. In the present case, MP progressed with chemotherapy. We concluded that mesenteric lesions suspected of progressing or recurring should be diagnosed pathologically even if asymptomatic.","PeriodicalId":12954,"journal":{"name":"Hematology Reviews","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76033863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pleural effusion directly attributable to multiple myeloma is exceedingly uncommon and is said to occur in only 1–2% of cases. Of these around 80% occur in IgA disease. We report a case of myelomatous pleural effusion (proven on cytological and immunohistochemical analysis) in a patient with the IgG-κ subtype. We describe the diagnosis, pathogenesis and management of this condition and show the radiological and cytological evidence of the case.
{"title":"Massive pleural effusion due to IgG multiple myeloma","authors":"K. Lang, S. Lidder, R. Aitchison","doi":"10.4081/hr.2009.e18","DOIUrl":"https://doi.org/10.4081/hr.2009.e18","url":null,"abstract":"Pleural effusion directly attributable to multiple myeloma is exceedingly uncommon and is said to occur in only 1–2% of cases. Of these around 80% occur in IgA disease. We report a case of myelomatous pleural effusion (proven on cytological and immunohistochemical analysis) in a patient with the IgG-κ subtype. We describe the diagnosis, pathogenesis and management of this condition and show the radiological and cytological evidence of the case.","PeriodicalId":12954,"journal":{"name":"Hematology Reviews","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77658634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：